Refers to a compound of formula (i) wherein: R1 and R2 are each h, c1-c4 alkyl, cycloalkyl, haloalquilo, alquenilo, among others R3 is H, cicloalquilalquilo, cicloalquenilo optionally replaced, alquinilo, among others l is a Linker of preference - CH2 -, - C (o) - Z1 and Z2 are each S, CRA is h V, optionally substituted aryl, cyano, Nitro,Among others, and is optionally substituted aryl isoxazole, thiazole, thiadiazole, imidazole, pyrazole, pyrimidine, among others ra is H, halogen, alkyl, cyano, haloalquilo, cicloalquilalquilo, among others.Preferred compounds are: 2 - (- 2.4 - 1.3 - dimethyl - 1,2,3,4 - cyclohexanecarboxylic tetrahidrotieno [2,3-d] pyrimidin-5-yl) - N - [4 - (trifluoromethyl) - 1,3 - thiazol-2-yl] acetamide n - [4 - (3,4-dichlorophenyl) - 1,3 - thiazole 2 - yl] - 2 - (- 2.4 - 1.3 - dimethyl - 1,2,3,4 - cyclohexanecarboxylic tetrahidrotieno [2,3-d] pyrimidin-5-yl) acetamide. In addition to such a Pharmaceutical composition.This Compound is a Derivative of the Transient Receptor Potential tienopirimidindiona Modulator of the subfamily (TRP) useful for treating or Preventing Diseases associated with Transient Receptor Potential of the subfamily a, member 1 (TRPA1)SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 Y R2 SON CADA UNO H, ALQUILO C1-C4, HALOALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS R3 ES H, CICLOALQUILALQUILO, CICLOALQUENILO OPCIONALMENTE SUSTITUIDO, ALQUINILO, ENTRE OTROS L ES UN LIGADOR DE PREFERENCIA -CH2-, -C(O)- Z1 Y Z2 SON CADA UNO S, CRa V ES H, ARILO OPCIONALMENTE SUSTITUIDO, CIANO, NITRO, ENTRE OTROS U ES ARILO OPCIONALMENTE SUSTITUIDO, TIAZOL, ISOXAZOL, IMIDAZOL, PIRAZOL, TIADIAZOL, PIRIMIDINA, ENTRE OTROS Ra ES H, CIANO, HALOGENO, ALQUILO, HALOALQUILO, CICLOALQUILALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROTIENO[2,3-d]PIRIMIDIN-5-IL)-N-[4-(TRIFLUOROMETIL)-1,3-TIAZOL-2-IL]ACETAMIDA N-[4-(3,4-DICLOROFENIL)-1,3-TIAZOL-2-IL]-2-(1,3-DIMETIL-2,4-DIOXO-1,2,3,4-TETRAHIDROTIENO[2,3-d]P
